IQWiG finds no hint of added benefit for Xadago in Parkinson's disease

20 August 2015

Following evaluation of dossiers relating to CNS specialist Zambon and its partner, fellow Italy-based Newron Pharmaceuticals’ (NWRN: SIX) Parkinson’s disease drug Xadago (safinamide), the German Institute for Quality and Efficiency in Health Care (IQWiG) concluded that an added benefit cannot be derived versus comparator drugs from the dossier, because relevant study data were not considered and the analyses were therefore incomplete.

Xadago was launched in Germany, its first market, in May 2015 as add-on therapy for the treatment of mid- to late-stage Parkinson’s disease in adults. In combination with levodopa alone or together with other Parkinson disease medicinal products, this monoamine oxidase (MAO-B) inhibitor is used to help restore dopamine levels in the brain.

Indirect comparison with limited study pool

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK